Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steffen Rausch

Showing results (121-130 of 124) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 124 results.
European Urology Oncology|August 21, 2023
Real-world Outcomes and Predictive Biomarkers for <sup>177</sup>Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational StudyMona Kafka, Andreas Horninger, Gianpaolo di Santo, et al.
Pharmacological Research|December 5, 2025
Drug targeting of the monocarboxylate transporter MCT4 is a novel treatment strategy for metastatic ccRCCLena-Sophie Menig-Benzig, Viktoria Stühler, Pascale Mazzola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2022
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin ResistanceNiklas Klümper, Damian J Ralser, Jörg Ellinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2024
<i>NECTIN4</i> Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial CancerNiklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, et al.
Pageof 13

Showing results (121-130 of 124) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 124 results.
European Urology Oncology|August 21, 2023
Real-world Outcomes and Predictive Biomarkers for <sup>177</sup>Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational StudyMona Kafka, Andreas Horninger, Gianpaolo di Santo, et al.
Pharmacological Research|December 5, 2025
Drug targeting of the monocarboxylate transporter MCT4 is a novel treatment strategy for metastatic ccRCCLena-Sophie Menig-Benzig, Viktoria Stühler, Pascale Mazzola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2022
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin ResistanceNiklas Klümper, Damian J Ralser, Jörg Ellinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2024
<i>NECTIN4</i> Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial CancerNiklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, et al.
Pageof 13